Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Monitoring Serum Bisoprolol Concentrations in Patients With Heart Failure With Reduced Ejection Fraction: Results of a Pilot Study From Routine Health Care

I. Kacirova, M. Lazarova, R. Urinovska, J. Dodulik, D. Drienikova, J. Vaclavik

. 2025 ; 13 (3) : e70089. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015464

Grantová podpora
MH CZ-DRO-FNOs/2023 Ministry of Health, Czech Republic

Bisoprolol is a second-generation, highly selective beta-1 adrenergic receptor antagonist with various beneficial effects in patients with heart failure. Interindividual variability in response to bisoprolol is known, and finding the optimal dose for individual patients with heart failure is still challenging. This pilot study included patients treated with bisoprolol for chronic heart failure with reduced ejection fraction. Between November 2022 and November 2023, one to six blood samples were collected from these patients to determine the trough serum concentration of bisoprolol. At the same time, the values of selected clinical variables were recorded. Bisoprolol concentrations ranged from 1.1 to 65.0 μg/L and correlated with both the daily dose and the dose per kilogram of body weight. However, wide variability in measured serum concentrations of bisoprolol was observed at the same daily dose and in apparent weight-adjusted clearance. Patients classified as NYHA III-IV received a 33% higher dose per kilogram of body weight than patients in NYHA I-II but achieved 165% higher serum concentrations of bisoprolol. An inverse correlation was found between diastolic blood pressure and dose per kilogram of body weight, and a positive correlation between N-terminal pro-B-type natriuretic peptide and both dose per kilogram of body weight and serum bisoprolol concentration. A wide variability in patients' serum concentrations of bisoprolol achieved after taking the same dose has been observed. A significantly higher concentration-to-dose ratio and a significantly lower weight-adjusted apparent clearance were demonstrated in patients with reduced cardiac function, reduced renal function, and taking the combination with amiodarone. These patients may be more prone to overdose with bisoprolol.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015464
003      
CZ-PrNML
005      
20250731091011.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/prp2.70089 $2 doi
035    __
$a (PubMed)40287796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kacirova, Ivana $u Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/000000016618754X $7 xx0081201
245    10
$a Monitoring Serum Bisoprolol Concentrations in Patients With Heart Failure With Reduced Ejection Fraction: Results of a Pilot Study From Routine Health Care / $c I. Kacirova, M. Lazarova, R. Urinovska, J. Dodulik, D. Drienikova, J. Vaclavik
520    9_
$a Bisoprolol is a second-generation, highly selective beta-1 adrenergic receptor antagonist with various beneficial effects in patients with heart failure. Interindividual variability in response to bisoprolol is known, and finding the optimal dose for individual patients with heart failure is still challenging. This pilot study included patients treated with bisoprolol for chronic heart failure with reduced ejection fraction. Between November 2022 and November 2023, one to six blood samples were collected from these patients to determine the trough serum concentration of bisoprolol. At the same time, the values of selected clinical variables were recorded. Bisoprolol concentrations ranged from 1.1 to 65.0 μg/L and correlated with both the daily dose and the dose per kilogram of body weight. However, wide variability in measured serum concentrations of bisoprolol was observed at the same daily dose and in apparent weight-adjusted clearance. Patients classified as NYHA III-IV received a 33% higher dose per kilogram of body weight than patients in NYHA I-II but achieved 165% higher serum concentrations of bisoprolol. An inverse correlation was found between diastolic blood pressure and dose per kilogram of body weight, and a positive correlation between N-terminal pro-B-type natriuretic peptide and both dose per kilogram of body weight and serum bisoprolol concentration. A wide variability in patients' serum concentrations of bisoprolol achieved after taking the same dose has been observed. A significantly higher concentration-to-dose ratio and a significantly lower weight-adjusted apparent clearance were demonstrated in patients with reduced cardiac function, reduced renal function, and taking the combination with amiodarone. These patients may be more prone to overdose with bisoprolol.
650    _2
$a lidé $7 D006801
650    12
$a bisoprolol $x krev $x aplikace a dávkování $x farmakokinetika $x terapeutické užití $7 D017298
650    _2
$a pilotní projekty $7 D010865
650    12
$a srdeční selhání $x farmakoterapie $x krev $x patofyziologie $7 D006333
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a antagonisté beta-1-adrenergních receptorů $x krev $x aplikace a dávkování $x farmakokinetika $x terapeutické užití $7 D058671
650    _2
$a lidé středního věku $7 D008875
650    _2
$a tepový objem $x účinky léků $7 D013318
650    _2
$a monitorování léčiv $7 D016903
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lazarova, Marie $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0009000118020574
700    1_
$a Urinovska, Romana $u Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000239818841
700    1_
$a Dodulik, Jozef $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0009000735370342
700    1_
$a Drienikova, Diana $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Vaclavik, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Internal Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $1 https://orcid.org/0000000178470967 $7 xx0169228
773    0_
$w MED00190080 $t Pharmacology research & perspectives $x 2052-1707 $g Roč. 13, č. 3 (2025), s. e70089
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40287796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091005 $b ABA008
999    __
$a ok $b bmc $g 2366353 $s 1252589
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 13 $c 3 $d e70089 $e - $i 2052-1707 $m Pharmacology research & perspectives $n Pharmacol Res Perspect $x MED00190080
GRA    __
$a MH CZ-DRO-FNOs/2023 $p Ministry of Health, Czech Republic
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace